AIB CEO Says Markets Are Calm Despite Trade, Mideast Uncertainty
Markets are 'extraordinarily calm' given the scale of the uncertainty surrounding global trade turmoil and increasing tensions in the Middle East, according to the head of Ireland's biggest bank.
'If you look at if you look at even oil prices, if you look at the the mix of geopolitical factors we're dealing with at the moment, including very significant tensions in the Middle East, you would not predict that the world's leading indices would be where they are.,' Colin Hunt, AIB Group Plc chief executive officer, told a panel at Bloomberg's Future of Finance in Ireland event.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
8 minutes ago
- Wall Street Journal
Stocks Rise and Oil Recedes After Iran's Retaliation Avoids Energy Infrastructure
Oil prices retreated and stocks climbed on Monday after Iran's retaliation against the U.S. avoided striking critical energy infrastructure, easing fears that the conflict in the Middle East would roil crude markets. U.S. oil futures fell 7.2% after Iran launched missiles at a U.S. base in Qatar and into Iraq, with no casualties reported. The drop was a sharp reversal from Sunday night, when U.S. oil prices surged more than 6% in response to the U.S. bombing of Iran's nuclear sites over the weekend.
Yahoo
16 minutes ago
- Yahoo
Amgen stock slips, weight-loss drug moves to phase 3 trial
Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with participants getting to the highest dose level through a three-step dose escalation. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. at Amgen revealing plans for phase three of its highly anticipated GLP1 maratide from over. Bringing in here, Yahoo! Finance senior health reporter, Anjalee Khemlani. Anj. That's right. So we got news from Amgen today, which is at the American Diabetes Association conference. That's why you're getting a flood of GLP1 news today. And their latest is that they've started enrolling for their phase three of maratide. Now remember, this drug is their weight loss drug that was is going to enter a market that is competing with Eli Lilly and Novo Nordisk. Currently the drug has about 20% weight loss for those without diabetes and 17%, and as you already can tell with those numbers, that's a little bit lower than what the com the com the competition on the market is, really being the lead with 24%. And so that's the market that's going to enter in. We do know that they have changed how they're doing the dosing for phase three, looking at a step up or three step up, and they did this in a phase one trial to kind of figure out because they were having some issues with tolerability, not abnormal for these kinds of drugs, but of course, trying to figure out how to make it more appealing for patients, and this is why. So looking at that, they are going to start off at 21 milligrams and then move all the way up, potentially to 350 milligrams. And that's sort of what we got from the from the company today, and we'll just have to wait and see how that phase three trial pans out, and then eventually when they do get to market. And Anj, what what exactly are investors looking for from Amgen? I mean, we know like GLP1s, ones are the hot thing. Weight loss drugs are such an area of interest for investors, and so you would think there would be all this enthusiasm here, but what specifically do they expect and do they want from Amgen to try to meet some of those other competitors? Yeah, so the tolerability was one part of it, but they're they've also kind of just been sort of mixed bag on the stock itself, wondering where Amgen gets to play. It's important to remember that this is a differentiated drug because it is going to be a one once a month injectable rather than the current weekly, and so that really reduces the burden on patients and it's a reason why a Jefferies analyst was saying earlier that it looks like really this could be the play. Amgen uh means uh, sorry, Amgen remains debated by investors, right? But they still get pretty good feedback from the doctors, and that's the part that they have to look at, is that what will what are the doctors going to be prescribing? Because at the end of the day, that's where the pickup is for the medication. And so if doctors like it, then they're going to be really more likely to prescribe it. And in addition to that, Amgen is also studying the drug for quarterly maintenance. They've noted that the drug has sort of a lack of plateauing at the end of the current study, and they're going to look and see whether or not more weight loss is possible, so it could still end up being competitive is what they think. So there's a lot to really wait and see on this drug right now. All right. Thank you, Anj. Appreciate it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
19 minutes ago
- Washington Post
How major US stock indexes fared Monday, 6/23/2025
U.S. stocks rallied, and oil prices tumbled on hopes that Iran will not disrupt the global flow of crude, even with the United States' entry into its war with Israel. A barrel of benchmark U.S. oil dropped more than 7% to $68.51 on Monday after briefly topping $78 Sunday night. The S&P 500 rose 1%, the Dow Jones Industrial Average added 0.9% and the Nasdaq composite gained 0.9%.
